Speed of Processing (SoP) Training Plus α-tACS (aMCIUp)

September 5, 2025 updated by: Portucalense University

Speed of Processing (SoP) Training Plus α-tACS in People With Mild Cognitive Impairment: a Double Blind, Parallel, Placebo Controlled Trial Study Protocol

The current proposal aims to assess if the combination of Speed of Processing (SoP) training with alpha tACS (α-tACS) is able to increase brain speed of processing as assessed by the Useful Field of View (UFOV) when comparing to SoP training plus sham α-tACS. Moreover, a second aim is to assess if those changes in speed of processing transfer to other cognitive domains, such as memory, language and executive functioning. Furthermore, the mechanisms underlying these interventions will be tested, namely to assess brain connectivity and coherence as assessed by EEG. To that purpose, the aim of the current proposal is to conduct a double-blind, parallel randomized trial assessing the effects of combining SoP with alpha endogenous tACS (either active or sham) in participants with Mild Cognitive impairment (MCI).

Study Overview

Detailed Description

Dementia is thought to affect 6.3 million people across Europe and is especially prevalent in people over 85 years old (23.7%). In this sense, several cognitive training programs, alone or in combination with non-invasive brain stimulation have been used in order to ameliorate age-related cognitive impairments, and even to act in a prophylactic manner in order to prevent more extreme deficits, such as the ones presented in mild cognitive impairment, or even dementia.

Despite all these efforts, the effects of CT - combined or not - with several forms of non-invasive brain stimulation have been modest at most.

The current proposal aims to assess if Speed of Processing (SoP) training combined with alpha tACS (α-tACS) increases speed of processing as assessed by the Useful Field of View (UFOV) when comparing to SoP training and sham α-tACS. Furthermore, association betweens changes in speed of processing and changes in other cognitive domains, such as memory, language and executive functioning will be assessed. Finnaly, the current proposal aims at probing the mechanisms underlying these interventions, namely to test brain connectivity and coherence as assessed by EEG.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Porto, Portugal, 4200 - 072
        • Portucalense University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Community-dwelling adults aged 65 years and older, with cognitive complains in memory or other functions, which have declined over time

Exclusion Criteria:

  • Score in the mini mental examination less than 23 (or over 28);
  • Diagnosis of Alzheimer´s Disease, any other medical condition that may predispose participants for a forthcoming decline in function, or that may increase their risk of mortality during the duration of the study.
  • Any contra-indication to tACS, severe sensory losses or communication difficulties that will prevent them from successfully complete the training.
  • Had any cognitive training in the past.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Active tACS plus active SoP
Active alpha range tACS plus Speed of Processing Training
2mA α-tACS (based on the IAF) over the prefrontal cortex (PFC)
SoP training will have a total of four conditions. In condition 1, participants will be asked to identity objects at increasingly brief exposures. For condition 2, identification of stimulus on the center of the screen will be requested from participants, while a second stimulus will appear somewhere in peripheral vision - stimulus duration, difficulty of the central localization task or the area in which targets may be located are used to change the level of difficulty. Condition 3 is similar to condition 2, but visual distractors are added. Finally, for condition 4, an auditory identification component is superimposed over the visual task (Jobe et al., 2001)
Active Comparator: Active tACS plus sham SoP
Active alpha range tACS plus sham Speed of Processing Training
2mA α-tACS (based on the IAF) over the prefrontal cortex (PFC)
Active Comparator: Sham tACS plus active SoP
Sham alpha range tACS plus Speed of Processing Training
SoP training will have a total of four conditions. In condition 1, participants will be asked to identity objects at increasingly brief exposures. For condition 2, identification of stimulus on the center of the screen will be requested from participants, while a second stimulus will appear somewhere in peripheral vision - stimulus duration, difficulty of the central localization task or the area in which targets may be located are used to change the level of difficulty. Condition 3 is similar to condition 2, but visual distractors are added. Finally, for condition 4, an auditory identification component is superimposed over the visual task (Jobe et al., 2001)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Useful Field of View Test (UFOV)
Time Frame: Change from baseline to week 3
UFOV is a measure of the speed of visual processing for rapid detection and localization of targets under conditions of divided visual attention and in the presence and absence of visual clutter at an above chance level (i.e. 75%).
Change from baseline to week 3
Useful Field of View (UFOV)
Time Frame: Change from baseline to week 6
UFOV is a measure of the speed of visual processing for rapid detection and localization of targets under conditions of divided visual attention and in the presence and absence of visual clutter at an above chance level (i.e. 75%).
Change from baseline to week 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Executive Composite Score from the Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (NIH EXAMINER)
Time Frame: Change from baseline to week 3
The NIH examiner executive composite comprises cognitive control, verbal fluency, and working memory assessments. Scores are based on the Item Response theory (IRT), which allows for the contribution of each item score is weighted by how effective that item measures that ability in any part of the continuum. Instead of a maximum or a minimum, higher scores, mean better performance.
Change from baseline to week 3
Executive Composite Score from the Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (NIH EXAMINER)
Time Frame: Change from baseline to week 6
The NIH examiner executive composite comprises cognitive control, verbal fluency, and working memory assessments. Scores are based on the Item Response theory (IRT), which allows for the contribution of each item score is weighted by how effective that item measures that ability in any part of the continuum. Instead of a maximum or a minimum, higher scores, mean better performance.
Change from baseline to week 6
EEG power in the alpha band
Time Frame: Change from baseline to week 3
Total Power
Change from baseline to week 3
EEG power in the alpha band
Time Frame: Change from baseline to week 6
Total Power
Change from baseline to week 6
P300 Event related potential - A
Time Frame: Change from baseline to week 3
Amplitude of the P300 potential
Change from baseline to week 3
P300 Event related potential - L
Time Frame: Change from baseline to week 3
Latency of the P300 potential
Change from baseline to week 3
P300 Event related potential - A
Time Frame: Change from baseline to week 6
Amplitude of the P300 potential
Change from baseline to week 6
P300 Event related potential - L
Time Frame: Change from baseline to week 6
Latency of the P300 potential
Change from baseline to week 6

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Useful Field of View (UFOV)
Time Frame: Change from baseline to 1 month follow-up (after intervention ended)
Measure of the speed of visual processing for rapid detection and localization of targets under conditions of divided visual attention and in the presence and absence of visual clutter at an above chance level (i.e. 75%).
Change from baseline to 1 month follow-up (after intervention ended)
Useful Field of View (UFOV)
Time Frame: Change from baseline to 3 months follow-up (after intervention ended)
Measure of the speed of visual processing for rapid detection and localization of targets under conditions of divided visual attention and in the presence and absence of visual clutter at an above chance level (i.e. 75%).
Change from baseline to 3 months follow-up (after intervention ended)
Useful Field of View (UFOV)
Time Frame: Change from baseline to 6 months follow-up (after intervention ended)
Measure of the speed of visual processing for rapid detection and localization of targets under conditions of divided visual attention and in the presence and absence of visual clutter at an above chance level (i.e. 75%).
Change from baseline to 6 months follow-up (after intervention ended)
Executive Composite Score from NIH EXAMINER
Time Frame: Change from baseline to 1 month follow-up (after intervention ended)
The NIH examiner comprises cognitive control, verbal fluency, and working memory assessments
Change from baseline to 1 month follow-up (after intervention ended)
Executive Composite Score from NIH EXAMINER
Time Frame: Change from baseline to 3 months follow-up (after intervention ended)
The NIH examiner comprises cognitive control, verbal fluency, and working memory assessments
Change from baseline to 3 months follow-up (after intervention ended)
Executive Composite Score from NIH EXAMINER
Time Frame: Change from baseline to 6 months follow-up (after intervention ended)
The NIH examiner comprises cognitive control, verbal fluency, and working memory assessments
Change from baseline to 6 months follow-up (after intervention ended)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jorge Leite, PhD, Portucalense University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 19, 2022

Primary Completion (Actual)

September 5, 2025

Study Completion (Actual)

September 5, 2025

Study Registration Dates

First Submitted

December 20, 2021

First Submitted That Met QC Criteria

January 6, 2022

First Posted (Actual)

January 20, 2022

Study Record Updates

Last Update Posted (Estimated)

September 12, 2025

Last Update Submitted That Met QC Criteria

September 5, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • UPT01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Deidentified and coded data will be available to researchers upon request

IPD Sharing Time Frame

Data will be available upon study completion.

IPD Sharing Access Criteria

Upon request.

IPD Sharing Supporting Information Type

  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Dysfunction

Clinical Trials on alpha tACS

Subscribe